文献速递浆细胞疾病

基于片段分析或二代测序的可测量残留病评估在多发性骨髓瘤中的预后价值的真实世界数据

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma.
PubMed 文献 · Br J Haematol · 2022-05-03

该研究在新诊断接受自体干细胞移植的多发性骨髓瘤患者中,评估基于克隆性分析的商业化可测量残留病检测(IdentiClone®片段分析,73例;LymphoTrack®二代测序,116例)的临床相关性。片段分析评估的可测量残留病不能预测生存,而二代测序评估的可测量残留病阴性在移植前或移植后均与无进展生存和总生存获益相关,且为独立相关因素。

要点

  • 片段分析评估的可测量残留病不能预测生存。
  • 二代测序评估的可测量残留病阴性在移植前或移植后均与无进展生存和总生存获益相关。
  • 二代测序可测量残留病阴性为独立于其他因素的预后良好指标,移植前后均阳性者结局最差。

核心结论

  • 商业化的基于克隆性分析的可测量残留病检测在多发性骨髓瘤中具有可行性及临床获益,支持将二代测序而非片段分析纳入真实世界实践以制定治疗策略。

研究设计与样本

  • 在新诊断多发性骨髓瘤并接受自体干细胞移植的患者中,采用IdentiClone®片段分析(73例)和LymphoTrack®二代测序(116例)评估可测量残留病。
  • 可测量残留病在诱导治疗结束时(移植前)和/或自体干细胞移植后100天(移植后)进行评估。

主要发现

  • 片段分析评估的可测量残留病不能预测生存。
  • 二代测序评估的可测量残留病阴性在移植前或移植后均与无进展生存和总生存获益相关。
  • 二代测序评估的可测量残留病阴性独立与改善的无进展生存和总生存相关,移植前和移植后均阳性的患者结局最差。
  • 通过二代测序达到可测量残留病阴性可减轻高危细胞遗传学所提示的初始不良预后特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) negativity is a strong prognostic indicator in multiple myeloma (MM). However, the optimal use of MRD in daily clinical practice has been hampered by the limited feasibility of MRD testing. Therefore, we examined the clinical relevance of commercially available MRD modalities based on clonality assays by fragment analysis with IdentiClone® (n = 73 patients) and next-generation sequencing (NGS) with LymphoTrack® (n = 116 patients) in newly diagnosed patients with MM who received autologous stem cell transplantation (ASCT). MRD was assessed at the end of induction (pre-ASCT) and/or at 100 days after ASCT (post-ASCT). MRD could not predict survival when assessed by fragment analysis. However, NGS-based MRD negativity at pre- or post-ASCT was beneficial in terms of progression-free and overall survival. Moreover, NGS-based MRD negativity was independently associated with improved progression-free and overall survival, and MRD-positive patients both pre- and post-ASCT had worst outcome. Indeed, initial adverse prognostic features by high-risk cytogenetics could be mitigated upon achieving MRD negativity by NGS. We demonstrate the feasibility and clinical benefit of achieving MRD negativity by commercially available clonality-based MRD assays in MM and support incorporating NGS, but not fragment analysis, to tailor therapeutic strategies in real-world practice.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cho H, Shin S, Chung H, et al. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma. Br J Haematol. 2022. PMID: 35505579. doi:10.1111/bjh.18211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。